StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the stock.
Several other equities research analysts have also recently weighed in on MBRX. Roth Mkm reiterated a buy rating and set a $40.00 price objective on shares of Moleculin Biotech in a research report on Friday, April 12th. Maxim Group reduced their price target on shares of Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a report on Tuesday, March 26th.
Get Our Latest Analysis on MBRX
Moleculin Biotech Stock Performance
Institutional Trading of Moleculin Biotech
Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. bought a new stake in shares of Moleculin Biotech in the fourth quarter valued at approximately $39,000. Atticus Wealth Management LLC bought a new stake in shares of Moleculin Biotech in the fourth quarter valued at approximately $43,000. Citadel Advisors LLC bought a new stake in shares of Moleculin Biotech in the fourth quarter valued at approximately $55,000. Renaissance Technologies LLC raised its position in shares of Moleculin Biotech by 34.7% in the second quarter. Renaissance Technologies LLC now owns 127,400 shares of the company’s stock valued at $74,000 after purchasing an additional 32,795 shares during the period. Finally, State Street Corp raised its position in shares of Moleculin Biotech by 19.2% in the first quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after purchasing an additional 11,497 shares during the period. Institutional investors own 15.52% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Silicon Motion Proves That AI in Motion Stays in Motion
- Quiet Period Expirations Explained
- Undervalued UnitedHealth Group Won’t Be For Long
- Election Stocks: How Elections Affect the Stock Market
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.